Platelet-derived RANKL then impairs NK antitumor reactivity with a more pronounced effect on IFNγ production as compared to cytotoxicity, which is again in line with observations on the differential effect of RANK/RANKL interaction on NK reactivity in hematological malignancies. This evidence concerns the gene TNFRSF11A and hematologic disorder.